Scarica l'app Stockscreener
55.16
0.97%
-0.54
Dopo l'orario di chiusura:
55.16
Anaptysbio Inc Borsa (ANAB) Ultime notizie
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage By Investing.com - Investing.com Canada
AnaptysBio earnings on deck: Jemperli lawsuit takes center stage - Investing.com
ANAB Q2'26 Earnings: EPS estimate is (0.47) USD - TradingView
Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB) - Yahoo Finance UK
Squarepoint Ops LLC Has $21.90 Million Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio, Inc. $ANAB Shares Purchased by Hsbc Holdings PLC - MarketBeat
U.S. Earnings Preview: After Market Close Sept. 8 - Moomoo
Irenic Capital Management LP Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Bank of New York Mellon Corp Makes New $3.81 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Anaptysbio Stock Price Forecast. Should You Buy ANAB? - StockInvest.us
ANAB Q2'26 Earnings: revenue estimate is 8.89M USD - TradingView
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
U.S. Earnings Preview: After Market Close Sept. 1 - Moomoo
AnaptysBio stock rating maintained at Outperform by Wolfe Research - Investing.com Nigeria
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? By Investing.com - Investing.com Australia
AnaptysBio earnings on deck: Can Jemperli offset revenue slide? - Investing.com
Empowered Funds LLC Makes New $13.91 Million Investment in AnaptysBio, Inc. $ANAB - MarketBeat
1,844,049 Shares in AnaptysBio, Inc. $ANAB Bought by BlackRock Inc. - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio Inc. (ANAB) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Palo Alto Investors LP Purchases Shares of 603,489 AnaptysBio, Inc. $ANAB - MarketBeat
Hsbc Holdings PLC Purchases Shares of 216,949 AnaptysBio, Inc. $ANAB - MarketBeat
Deutsche Bank AG Makes New Investment in AnaptysBio, Inc. $ANAB - MarketBeat
Is AnaptysBio (ANAB) Undervalued Or Has Its Royalty Story Already Been Priced In? - Sahm
ANAB Maintained by TD Cowen -- Price Target Lowered to $70 - GuruFocus
TD Cowen lowers Anaptysbio stock price target to $70 on FDA review - Investing.com UK
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating - Moomoo
AnaptysBio, Inc. (ANAB) Earnings Preview: The First Full Royalty-Model Quarter Matters More Than the Headline EPS - AlphaStreet
TD Cowen Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $70 - Moomoo
AnaptysBio (NASDAQ:ANAB) Given Buy Rating at HC Wainwright - MarketBeat
Greenhaven Road Investment Management, L.P.'s AnaptysBio Inc(ANAB) Holding History - GuruFocus
AnaptysBio (NASDAQ:ANAB): High Growth Momentum Aligns With a Breakout Setup - ChartMill
U.S. Earnings Preview: After Market Close Aug. 18 - Moomoo
US High Growth Tech Stocks To Watch In August 2026 - simplywall.st
GSK Eyes AnaptysBio (ANAB) Acquisition to Secure Drug Control - Yahoo Finance
Bank of America Corp DE Boosts Stock Position in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio earnings ahead: First results as royalty company By Investing.com - Investing.com Canada
AnaptysBio earnings ahead: First results as royalty company - Investing.com
AnaptysBio (NASDAQ:ANAB) Shares Pass Above Fifty Day Moving AverageHere's What Happened - MarketBeat
AnaptysBio (ANAB) Holds Steady at $56.09: Key Levels to WatchNew Listing Stocks - vinanet.vn
Sirenia Capital discloses 5.0% AnaptysBio (ANAB) ownership in Schedule 13G/A - Stock Titan
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Buy Rating, Maintains Target Price $95 - Moomoo
AnaptysBio Shareholders Back Board, Governance and Incentives - theglobeandmail.com
AnaptysBio Announces Results of 2026 Annual Stockholders Meeting Voting - Kalkine Media
AnaptysBio (ANAB) Climbs 4.33% to $57.87 as Biotech Momentum BuildsETF NAV Deviation - vinanet.vn
Is AnaptysBio (ANAB) Undervalued After Its Recent Share Price Swings? - Sahm
Price-Driven Insight from (ANAB) for Rule-Based Strategy - Stock Traders Daily
AnaptysBio (ANAB) Rallies 3.36% as Biotech Momentum Builds Toward Key ResistanceGolden Cross - dars.gov.et
AnaptysBio (ANAB) awards CEO 53,334 performance stock units - Stock Titan
AnaptysBio (NASDAQ: ANAB) awards 16,667 performance stock units to its CMO - Stock Titan
AnaptysBio Inc (ANAB) Stock News Today - TradingKey
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? - Investing.com
AnaptysBio earnings ahead: Can royalty revenue offset spinoff volatility? By Investing.com - Investing.com Canada
ANAB Q2'26 Earnings: EPS estimate is (0.13) USD - TradingView
AnaptysBio, Inc. (ANAB) Stock Analysis: Exploring a 59% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):